公开(公告)号：US20200285714A9

公开(公告)日：2020-09-10

申请号：US16030296

申请日：2018-07-09

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Ayman S. El-Baz ,  Ahmed Shalaby ,  Fahmi Khalifa ,  Islam Abdelmaksoud

IPC: G06F19/24 ,  G06F19/12

Abstract: Systems and methods for diagnosing prostate cancer. Image sets (e.g., MRI collected at one or more b-values) and biological values (e.g., prostate specific antigen (PSA)) have features extracted and integrated to produce a diagnosis of prostate cancer. The image sets are analyzed primarily in three steps: (1) segmentation, (2) feature extraction, smoothing, and normalization, and (3) classification. The biological values are analyzed primarily in two steps: (1) feature extraction and (2) classification. Each analysis results in diagnostic probabilities, which are then combined to pass through an additional classification stage. The end result is a more accurate diagnosis of prostate cancer.

公开(公告)号：US20200089842A1

公开(公告)日：2020-03-19

申请号：US16134222

申请日：2018-09-18

Applicant: International Business Machines Corporation

Inventor： Raphael Polig ,  Mitra Purandare

IPC: G06F19/12 ,  G06F19/22 ,  G06F17/50

Abstract: A random sequence generation of defined values may be provided. A method comprises pre-loading a RAM block with an initial list comprising the defined values of a sequence of values to be updated, and shuffling the defined values of the sequence using a counter and a random offset for indices in the list.

公开(公告)号：US20200012761A1

公开(公告)日：2020-01-09

申请号：US16030296

申请日：2018-07-09

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Ayman S. El-Baz ,  Ahmed Shalaby ,  Fahmi Khalifa ,  Islam Abdelmaksoud

IPC: G06F19/24 ,  G06F19/12

Abstract: Systems and methods for diagnosing prostate cancer. Image sets (e.g., MRI collected at one or more b-values) and biological values (e.g., prostate specific antigen (PSA)) have features extracted and integrated to produce a diagnosis of prostate cancer. The image sets are analyzed primarily in three steps: (1) segmentation, (2) feature extraction, smoothing, and normalization, and (3) classification. The biological values are analyzed primarily in two steps: (1) feature extraction and (2) classification. Each analysis results in diagnostic probabilities, which are then combined to pass through an additional classification stage. The end result is a more accurate diagnosis of prostate cancer.

公开(公告)号：US20190384889A1

公开(公告)日：2019-12-19

申请号：US16011231

申请日：2018-06-18

Applicant: International Business Machines Corporation

Inventor： Zhaonan Sun ,  Zach Shahn ,  Ping Zhang ,  Fei Wang ,  Jianying Hu

IPC: G06F19/12 ,  G06F19/18 ,  G16H50/30 ,  G16H10/60

Abstract: Techniques are described that facilitate determining potential cancer gene therapy targets by joint modeling of cancer survival events. In one embodiment, a computer-implemented comprises employing, by a device operatively coupled to a processor, a multi-task learning model to determine active genetic factors respectively associated with different types of cancer based on cancer survival data and patient genomic data for groups of patients that respectively survived the different types of cancer. The computer-implemented method further comprises, determining, by the device, common active genetic factors of the active genetic factors that are shared between two or more types of cancer of the different types of cancer.

公开(公告)号：US10436771B2

公开(公告)日：2019-10-08

申请号：US15480327

申请日：2017-04-05

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Benedict Anchang ,  Sylvia K. Plevritis

IPC: G01N33/50 ,  G06F19/26 ,  G01N33/68 ,  G06F19/12 ,  G16B5/00 ,  G16B45/00 ,  G01N33/569 ,  G16H10/40 ,  G06F19/00

Abstract: Systems and methods for targeted therapy based on single-cell stimulus perturbation response. In one embodiment, a method for optimizing stimulus combinations for therapy includes receiving a cell sample, treating the cell sample with a plurality of stimuli by treating a different portion of the cell sample with one of the plurality of stimuli for each of the plurality of stimuli, labeling the cell sample with a plurality of metal-conjugated probes, analyzing the cell sample using a mass spectrometer, obtaining mass spectrometry data from the mass spectrometer, identifying subpopulations within the cell sample using the mass spectrometry data, computing stimulus effects, generating a nested-effects model using the mass spectrometry data, and scoring stimuli combinations using the computing device, wherein the stimulus combinations are combinations made from the plurality of stimuli.

公开(公告)号：US20190188359A1

公开(公告)日：2019-06-20

申请号：US16145722

申请日：2018-09-28

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Anja VAN DE STOLPE ,  Laurentius Henricus Franciscus Maria HOLTZER

IPC: G06F19/20 ,  G06F19/18 ,  G06F19/00 ,  G06N5/02 ,  G06N7/00 ,  G06N99/00 ,  G06F19/12 ,  G16H50/20 ,  G16H50/30

CPC classification number: G16B25/00 ,  C12Q1/6886 ,  C12Q2600/158 ,  G06N5/02 ,  G06N7/005 ,  G06N20/00 ,  G16B5/00 ,  G16B20/00 ,  G16C20/70 ,  G16H20/10 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50

Abstract: A bioinformatics process which provides an improved means to detect a MAPK-AP-1 cellular signaling pathway in a subject, such as a human, based on the expression levels of at least three unique target genes of the MAPK-AP-1 cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of MAPK-AP-1 cellular signaling pathway target genes.

公开(公告)号：US10321958B2

公开(公告)日：2019-06-18

申请号：US14986272

申请日：2015-12-31

Applicant: HeartFlow, Inc.

Inventor： Charles A. Taylor

IPC: G06G7/48 ,  A61B34/10 ,  G06F17/10 ,  A61B34/00 ,  A61B5/02 ,  A61B5/026 ,  G06G7/60 ,  G06F19/26 ,  A61B5/00 ,  A61B5/029 ,  A61B6/03 ,  A61B6/00 ,  A61B8/06 ,  A61B8/08 ,  G01R33/563 ,  A61B5/107 ,  G06T7/00 ,  G06T17/00 ,  G06K9/00 ,  G06K9/62 ,  A61B5/021 ,  G06F17/50 ,  G06F19/12 ,  A61B5/024 ,  A61B5/22 ,  G06F19/00 ,  G06K9/46 ,  G06T7/20 ,  G06T11/00 ,  G06T11/20 ,  A61M5/00 ,  G06K9/52 ,  A61B5/055 ,  A61B5/11 ,  G06T17/20 ,  G06T15/10 ,  G06T11/60 ,  G06T7/60 ,  A61B8/02 ,  A61B8/04 ,  G06T7/70 ,  G06T7/73 ,  G06T7/11 ,  G06T7/12 ,  G06T7/13 ,  G06T7/149 ,  G06T7/62 ,  G01R33/56 ,  G16H10/60 ,  G16H50/30 ,  G16H50/50 ,  G16H30/20 ,  G16H30/40 ,  G16H10/40 ,  G16H50/70 ,  A61B90/00

Abstract: Embodiments include a system for determining cardiovascular information for a patient. The system may include at least one computer system configured to receive patient-specific data regarding a geometry of the patient's heart, and create a three-dimensional model representing at least a portion of the patient's heart based on the patient-specific data. The at least one computer system may be further configured to create a physics-based model relating to a blood flow characteristic of the patient's heart and determine a fractional flow reserve within the patient's heart based on the three-dimensional model and the physics-based model.

公开(公告)号：US20190179998A9

公开(公告)日：2019-06-13

申请号：US16006129

申请日：2018-06-12

Applicant: BostonGene Corporation

Inventor： Feliks Frenkel ,  Nikita Kotlov ,  Alexander Bagaev ,  Maksym Artomov ,  Ravshan Ataullakhanov

IPC: G06F19/12 ,  G06F19/18 ,  G06F17/18

Abstract: Techniques for determining whether a subject is likely to respond to an immune checkpoint blockade therapy. The techniques include obtaining expression data for the subject, using the expression data to determine subject expression levels for at least three genes selected from the set of predictor genes consisting of BRAF, ACVR1B, MPRIP, PRKAG1, STX2, AGPAT3, FYN, CMIP, ROBO4, RAB40C, HAUS8, SNAP23, SNX6, ACVR1B, MPRIP, COPS3, NLRX1, ELAC2, MON1B, ARF3, ARPIN, SPRYD3, FLI1, TIRAP, GSE1, POLR3K, PIGO, MFHAS1, NPIPA1, DPH6, ERLIN2, CES2, LHFP, NAIF1, ALCAM, SYNE1, SPINT1, SMTN, SLCA46A1, SAP25, WISP2, TSTD1, NLRX1, NPIPA1, HIST1H2AC, FUT8, FABP4, ERBB2, TUBA1A, XAGE1E, SERPINF1, RAI14, SIRPA, MT1X, NEK3, TGFB3, USP13, HLA-DRB4, IGF2, and MICAL1; and determining, using the determined expression levels and a statistical model trained using expression data indicating expression levels for a plurality of genes for a plurality of subjects, whether the subject is likely to respond to the immune checkpoint blockade therapy.

公开(公告)号：US10248758B2

公开(公告)日：2019-04-02

申请号：US14759308

申请日：2014-02-07

Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： David Baker ,  Neil King ,  Jacob Bale ,  William Sheffler

IPC: G06F19/18 ,  C07K14/00 ,  G01N33/68 ,  G06F19/16 ,  G06F19/12 ,  C07K14/195 ,  B82Y5/00

Abstract: Synthetic nanostructures, proteins that are useful, for example, in making synthetic nanostructures, and methods for designing such synthetic nanostructures are disclosed herein.

公开(公告)号：US10248757B2

公开(公告)日：2019-04-02

申请号：US14103259

申请日：2013-12-11

Applicant: Wayne State University

Inventor： Sorin Draghici ,  Zhonghui Xu ,  Michele Donato

IPC: G06F7/60 ,  G06F17/10 ,  G06F19/12 ,  G06F17/50 ,  G06F19/18

Abstract: Identifying pathways that are significantly impacted in a given condition is a crucial step in the understanding of the underlying biological phenomena. All approaches currently available for this purpose calculate a p-value that aims to quantify the significance of the involvement of each pathway in the given phenotype. These p-values were previously thought to be independent. Here, we show that this is not the case, and that pathways can affect each other's p-values through a “crosstalk” phenomenon that affects all major categories of existing methods. We describe a novel technique able to detect, quantify, and correct crosstalk effects, as well as identify novel independent functional modules. We assessed this technique on data from four real experiments coming from three phenotypes involving two species.